Grufity logoGrufity logo
StocksFundsSearch Filings

MEDNAX Inc Stock Research

MD

13.36USD+0.09(+0.68%)Delayed

Market Summary

USD13.36+0.09
Delayed
0.68%

MD Alerts

MD Stock Price

MD RSI Chart

MD Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

10.98

Price/Sales (Trailing)

0.56

EV/EBITDA

5.43

Price/Free Cashflow

6.83

MD Price/Sales (Trailing)

MD Profitability

EBT Margin

4.13%

Return on Equity

7.44%

Return on Assets

2.83%

Free Cashflow Yield

14.63%

MD Fundamentals

MD Revenue

Revenue (TTM)

2.0B

Revenue Y/Y

1.82%

Revenue Q/Q

-4.44%

MD Earnings

Earnings (TTM)

101.7M

Earnings Y/Y

167.05%

Earnings Q/Q

-52.1%

Price Action

52 Week Range

12.8423.95
(Low)(High)

Last 7 days

-2.1%

Last 30 days

-4.9%

Last 90 days

-14.6%

Trailing 12 Months

-30.7%

MD Financial Health

Current Ratio

1

MD Investor Care

Buy Backs (1Y)

4.07%

Diluted EPS (TTM)

1.22

Peers (Alternatives to MEDNAX)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
73.0B
60.9B
-4.91% 25.24%
12.73
1.2
1.94% -15.77%
20.7B
14.8B
-2.77% -13.32%
16.22
1.39
-6.96% -52.35%
15.0B
9.6B
-8.90% -4.59%
18.89
1.56
-10.08% -57.84%
MID-CAP
9.9B
13.6B
-10.37% 3.84%
14.64
0.74
5.04% -26.87%
8.5B
11.7B
9.28% -3.24%
16.63
0.73
0.42% -43.11%
7.2B
19.4B
-1.91% 7.28%
7.07
0.37
0.01% -33.70%
6.1B
4.4B
-5.92% 18.26%
22.47
1.4
8.15% -30.89%
4.5B
2.6B
-10.50% -11.04%
-48.8
1.71
13.01% -143.24%
3.4B
6.4B
-7.51% 11.50%
19.08
0.54
2.26% -46.98%
SMALL-CAP
1.7B
1.5B
6.01% 44.82%
-126.07
1.14
10.24% -173.11%
1.4B
976.1M
-21.09% 3.91%
28.65
1.47
10.19% 12.37%
645.6M
2.9B
-18.53% -39.08%
-3.53
0.22
7.97% -101.02%
419.8M
12.2B
-47.61% -42.62%
-104.96
0.03
-2.06% -101.36%
6.7M
46.8M
-7.74% -13.61%
-2.44
0.14
12.07% -154.21%

Financials for MEDNAX

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue0.4%1,9811,9721,9571,9601,947
Operating Expenses1.0%1,8171,7991,7521,7441,731
  S&GA Expenses-1.0%229231239248258
EBITDA-16.5%157188200202-
EBITDA Margin-17.2%0.08*0.10*0.10*0.10*-
Earnings Before Taxes60.3%13081.00107112106
EBT Margin-24.6%0.04*0.05*0.06*0.05*-
Interest Expenses-3.6%38.0040.0046.0054.0063.00
Net Income53.4%10266.0084.0084.0092.00
Net Income Margin-21.8%0.03*0.04*0.04*0.05*-
Free Cahsflow48.4%16711290.0061.00-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-1.2%2,3202,3482,3322,3702,341
  Current Assets-4.5%409428424459440
    Cash Equivalents-37.7%6.0010.009.0014.007.00
  Net PPE-0.5%73.0073.0072.0072.0072.00
  Goodwill0%1,5321,5321,5321,5321,529
Liabilities-3.2%1,4101,4561,4731,5241,464
  Current Liabilities-33.4%284427352329270
Shareholder's Equity2.0%910892859845877
  Retained Earnings16.0%-74.86-89.06-118-149-176
  Additional Paid-In Capital0.3%9879849819971,054
Shares Outstanding0.8%84.0083.0083.0084.0087.00
Minority InterestNaN%-----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-2.1%16416711290.0061.00
  Share Based Compensation-8.8%15.0016.0017.0018.0020.00
Cashflow From Investing26.2%-42.03-56.95-61.30-96.42-68.98
Cashflow From Financing74.9%-122-487-400-317-254
  Buy Backs-0.4%88.0089.0087.0068.004.00

Risks for MD

What is the probability of a big loss on MD?

100%


Probability that MEDNAX stock will be more than 20% underwater in next one year

84.2%


Probability that MEDNAX stock will be more than 30% underwater in next one year.

63.9%


Probability that MEDNAX stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if MEDNAX was unfortunately bought at previous high price.

Drawdowns

Returns for MD

Cumulative Returns on MD

-11.7%


10-Year Cumulative Returns

-20.8%


7-Year Cumulative Returns

-22.2%


5-Year Cumulative Returns

-5.6%


3-Year Cumulative Returns

What are the long-term rolling returns for MD?

FIve years rolling returns for MEDNAX.

Annualized Returns

Which funds bought or sold MD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
reduced
-8.15
-15,040
176,862
-%
2023-05-25
Legato Capital Management LLC
unchanged
-
1,426
425,382
0.08%
2023-05-23
Capital Impact Advisors, LLC
added
6.26
37,591
605,763
0.74%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-1.54
-79,701
6,614,300
-%
2023-05-18
JPMORGAN CHASE & CO
added
19.32
306,000
1,857,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-3.22
-668,000
22,438,000
0.03%
2023-05-17
Advisory Services Network, LLC
sold off
-
-
-
-%
2023-05-17
Thrivent Financial for Lutherans
reduced
-3.38
-38,000
1,213,000
-%
2023-05-16
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC
sold off
-100
-805,100
-
-%
2023-05-16
CAROLINAS WEALTH CONSULTING LLC
unchanged
-
11.00
3,221
-%

1–10 of 47

Latest Funds Activity

Are funds buying MD calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own MD
No. of Funds

MEDNAX News

Marketscreener.com
Concerned Shareholders of Cano Health Nominate Highly Qualified, Independent Director Candidates and Propose Removal of Dr. Marlow Hernandez from Board for Cause.
Marketscreener.com,
11 days ago
Radiology Business
InvestorsObserver
DLA Piper
Michael Slovak.
DLA Piper,
5 months ago
The Business Journals
American Medical Association
Digital Medicine Payment Advisory Group.
American Medical Association,
6 months ago
The Business Journals
The Business Journals

Schedule 13G FIlings of MEDNAX

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 10, 2023
alliancebernstein l.p.
10.0%
8,392,304
SC 13G/A
Feb 14, 2023
alliancebernstein l.p.
7.8%
6,468,122
SC 13G/A
Feb 14, 2023
earnest partners llc
7.9%
6,546,580
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
11.72%
9,738,017
SC 13G/A
Jan 23, 2023
blackrock inc.
16.5%
13,672,143
SC 13G/A
Jan 20, 2023
starboard value lp
4.0%
3,348,578
SC 13D/A
Dec 02, 2022
starboard value lp
7.1%
5,915,000
SC 13D/A
Feb 14, 2022
arrowmark colorado holdings llc
3.10%
2,683,879
SC 13G/A
Feb 14, 2022
alliancebernstein l.p.
8.5%
7,359,083
SC 13G/A

MD Fair Value

MEDNAX fair value in different scenarios

The table shows the Fair Value estimates for MEDNAX for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

11.32

-15.27%

14.02

4.94%

20.33

52.17%

26.00

94.61%

30.28

126.65%
Current Inflation

10.98

-17.81%

13.52

1.20%

19.29

44.39%

24.45

83.01%

27.50

105.84%
Very High Inflation

10.53

-21.18%

12.86

-3.74%

17.95

34.36%

22.49

68.34%

24.17

80.91%

Historical MEDNAX Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of MEDNAX

View All Filings
Date Filed Form Type Document
May 26, 2023
4
Insider Trading
May 24, 2023
144
Notice of Insider Sale Intent
May 22, 2023
4
Insider Trading
May 19, 2023
144
Notice of Insider Sale Intent
May 18, 2023
144
Notice of Insider Sale Intent
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading

Latest Insider Trading transactions for MD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-25
ORDAN MARK S
sold
-437,580
13.26
-33,000
-
2023-05-19
Weis Shirley A
sold
-13,725
13.63
-1,007
-
2023-05-18
Weis Shirley A
sold
-243,805
13.55
-17,993
-
2023-05-15
Pickert Curtis
gifted
-
-
-5,984
evp, chief operating officer
2023-05-12
Young Sylvia Jean
acquired
-
-
10,831
-
2023-05-11
Starcher John M. Jr.
acquired
-
-
10,965
-
2023-05-11
Linynsky Laura A
acquired
-
-
10,965
-
2023-05-11
SANSONE GUY P
acquired
-
-
10,965
-
2023-05-11
Weis Shirley A
acquired
-
-
10,965
-
2023-05-11
Rucker Michael A.
acquired
-
-
10,965
-

1–10 of 50

Mark S. Ordan
7420
MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was founded in 1979 and is based in Sunrise, Florida.

MD Income Statement

2023-03-31
Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]  
Net revenue$ 491,008$ 482,229
Operating expenses:  
Practice salaries and benefits362,235343,155
Practice supplies and other operating expenses30,72028,489
General and administrative expenses59,05961,287
Depreciation and amortization8,9538,769
Transformational and restructuring related expenses01,421
Total operating expenses460,967443,121
Income from operations30,04139,108
Investment and other income634875
Interest expense(10,390)(11,818)
Loss on early extinguishment of debt0(57,016)
Equity in earnings of unconsolidated affiliate427505
Total non-operating expenses(9,329)(67,454)
Income (loss) from continuing operations before income taxes20,712(28,346)
Income tax benefit(6,506)7,401
Income (loss)from continuing operations14,206(20,945)
Loss from discontinued operations, net of tax0(247)
Net Income (loss)14,206(21,192)
Net loss attributable to noncontrolling interest04
Net Income (loss) attributable to Pediatrix Medical Group, Inc.14,206(21,188)
Unrealized holding gain (loss) on investments, net of tax of $227 and $894604(2,668)
Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc.$ 14,810$ (23,856)
Net (loss) income attributable to Pediatrix Medical Group, Inc.:  
Basic$ 0.17$ (0.25)
Diluted$ 0.17$ (0.25)
Weighted average common shares:  
Basic81,89485,405
Diluted[1]82,31885,405
[1]

(a) Due to a loss from continuing operations for the three months ended March 31, 2022, 0.9 million incremental shares are not included because the effect would be antidilutive.

MD Balance Sheet

2023-03-31
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 6,124$ 9,824
Short-term investments96,70993,239
Accounts receivable, net278,739296,787
Prepaid expenses14,95114,878
Other current assets12,06913,261
Total current assets408,592427,989
Property and equipment, net72,92873,290
Goodwill1,532,0921,532,092
Intangible assets, net17,48718,491
Operating and finance lease right-of-use assets66,79366,924
Deferred income tax assets102,778105,925
Other assets119,381123,176
Total assets2,320,0512,347,887
Current liabilities:  
Accounts payable and accrued expenses226,675374,225
Current portion of debt and finance lease liabilities, net14,91414,898
Current portion of operating lease liabilities21,05821,589
Income taxes payable21,57116,271
Total current liabilities284,218426,983
Line of credit114,0004,000
Long-term debt and finance lease liabilities, net628,814632,381
Long-term operating lease liabilities43,97744,213
Long-term professional liabilities268,922275,629
Deferred income tax liabilities32,70333,638
Other liabilities37,64639,411
Total liabilities1,410,2801,456,255
Commitments and contingencies
Shareholders' equity:  
Preferred stock; $.01 par value; 1,000 shares authorized; none issued00
Common stock; $.01 par value; 200,000 shares authorized; 83,634 and 82,947 sharesissued and outstanding, respectively836829
Additional paid-in capital986,923983,601
Accumulated other comprehensive loss(3,131)(3,735)
Retained deficit(74,857)(89,063)
Total shareholders' equity909,771891,632
Total liabilities and shareholders' equity$ 2,320,051$ 2,347,887